Yunhai Biotech has been selected for the first batch of "Top Solver" projects at the National Precision Medicine Industry Innovation Center

On November 28, 2024, the Precision Medicine Industry Innovation and Development Seminar and the Science and Technology Enterprise Incubator Launch Ceremony were held at the Jinjiang Hotel in Chengdu.

The conference aimed to promote scientific and technological innovation and industry integration in the field of precision medicine, accelerating the development of new quality productive forces. The event attracted numerous experts and industry leaders from government, universities, research institutes, and enterprises to discuss the future direction of precision medicine.

At the conference, the National Precision Medicine Industry Innovation Center officially announced the shortlist for the first batch of "Top Solver" projects. Yunhai Biotech stood out among many technology companies and was successfully selected for the first batch of "Top Solver" projects. The list, focusing on precision diagnosis, precision treatment, and precision evaluation, selected several teams from well-known universities and research institutes such as Tsinghua University, Sichuan University, and Shanghai Jiao Tong University, as well as leading technology companies in the industry. These teams became the solvers in 15 key areas such as "Nucleic Acid Innovative Drug Development," "Targeted Gene Sequencing," "Precision Molecular Diagnosis," and "Microfluidic Chips," working together on technical research and industrial transformation. Through interdisciplinary technical research and industrial transformation, they promote the innovative development of the biopharmaceutical industry.

"Implementing key research projects with the 'Top Solver' approach provides us with strong research support in equipment, funding, and platforms. We will also adhere to the spirit of technology leadership and continuous innovation, accelerating the development of key core technologies to build a new highland for precision medicine research," said Professor Jinhong Guo, a representative of the project team.

Professor Yunfeng Lin from Yunhai Biotech was invited to attend the conference and gave a keynote speech titled "Framework Nucleic Acid Drugs." In his speech, Professor Lin detailed the latest progress in the development of framework nucleic acid drugs, shared breakthroughs and cutting-edge trends in the field, as well as exchanges and cooperation with precision medicine technologies.

The shortlisted projects and released results cover several sub-fields of biopharmaceuticals, with broad market prospects and tremendous development potential. Being selected for the "Top Solver" project signifies that Yunhai Biotech's research and development strength and technological innovation capabilities in the field of precision medicine have been highly recognized by the industry. Looking forward, Yunhai Biotech will continue to lead with framework nucleic acid technology, continuously promote scientific research innovation, and work with industry partners to advance the progress and development of precision medicine.